LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients

Therapies targeting SRC family kinases (SFKs) have shown efficacy in treating non-small cell lung cancer (NSCLC). However, recent clinical trials have found that the SFK inhibitor dasatinib is ineffective in some patient cohorts. Regardless, dasatinib treatment may benefit some NSCLC patient subgrou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yu Jin, Hong, Sungyoul, Sung, Minjung, Park, Min Jeong, Jung, Kyungsoo, Noh, Ka-Won, Oh, Doo-Yi, Lee, Mi-Sook, Oh, Ensel, Shin, Young Kee, Choi, Yoon-La
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347739/
https://www.ncbi.nlm.nih.gov/pubmed/27756880
http://dx.doi.org/10.18632/oncotarget.12657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347739/
https://www.ncbi.nlm.nih.gov/pubmed/27756880
http://dx.doi.org/10.18632/oncotarget.12657

Ejemplares similares